Lik Voon KiewCheong Soon KengErnidila RamliKhalifah SidikLip Yong ChungLim Tuck Meng2024-11-042024-11-042012-05http://onlinelibrary.wiley.com/doi/10.1002/ddr.21012https://dspace-cris.utar.edu.my/handle/123456789/6130This study assessed the in vivo antitumor efficacy of a polypeptide‐based poly‐L‐glutamic acid‐gemcitabine conjugate (PG‐G). PG‐G was synthesized by conjugating gemcitabine to poly‐L‐glutamic acid by a carbodiimide reaction. PG‐G was evaluated for its in vivo antitumor efficacy and toxicity using 4T1 murine breast tumor‐bearing mice. The antitumor effects of PG‐G were superior to those of unconjugated gemcitabine in both single and four‐consecutive dosing studies. Tumor regression was observed within 1 day after PG‐G administration and continued for 4–5 days. Thereafter, tumors grew at a slower rate compared with the unconjugated gemcitabine treatment group and other control groups. The main toxicity observed from the Berlin test was an apparent reversible weight loss of 10–12%. The unconjugated gemcitabine treatment group also demonstrated a similar, but reduced, weight loss trend. The present study demonstrates that the PG‐G formulation exhibits a significant antitumor activity in the aspects of tumor growth inhibition and shrinkage that is more robust than the parent drug and other control groups. Thus, the PG‐G dose regimen may be optimized to minimize side effects and render it a potential anticancer therapeutic.journal-article